Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 283

Sort by

Sort Order Select

Journal Articles

Post-induction minimal residual disease assessment by flow cytometry and molecular biology enables prognostic stratification of patients with NPM1-mutated Acute Myeloid Leukemia: A dataml registry study.

Blood (2025) 146 (Supplement 1): 1744.

https://doi.org/10.1182/blood-2025-1744

Published: 2025

Journal Articles

Comprehensive mutational profiling and clinical outcome of adults AML with NUP98 rearrangement

Blood (2025) 146 (Supplement 1): 7002.

https://doi.org/10.1182/blood-2025-7002

Published: 2025

Journal Articles

Impact of midostaurin in younger AML patients intensively treated with high-dose anthracycline

Blood (2025) 146 (Supplement 1): 1682.

https://doi.org/10.1182/blood-2025-1682

Published: 2025

Journal Articles

Real life study of ivosidenib in either monotherapy or combined with azacytidine for first line mutant IDH1 AML: A study from the french AML intergroup ALFA/filo

Blood (2025) 146 (Supplement 1): 1658.

https://doi.org/10.1182/blood-2025-1658

Published: 2025

Journal Articles

The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy

Sarah Bertoli, Niklas Landberg, Emilie Bérard, Camille Gondran, Laetitia Largeaud, Véronique De Mas, Pierre-Yves Dumas, Arnaud Pigneux, Audrey Bidet, Sylvain Garciaz, Ludovic Gabellier, Gabrielle Roth-Guepin, Corentin Orvain, Pierre Peterlin, Rudy Birsen, Magda Alexis, Martin Carre, Emmanuelle Tavernier, Marion Boissard Simonet, Chantal Himberlin, Marc Maynadié, Kamel Laribi, Cécile Moluçon-Chabrot, Amine Belhabri, Samy Chraibi, Quentin Cabrera, Delphine Lebon, Emmanuel Raffoux, Thomas Cluzeau, Jean-Baptiste Micol, Mathieu Leclerc, Céline Berthon, Herve Dombret, Gunnar Juliusson, Anna Robelius, Sören Lehmann, Martin Jädersten, Lovisa Wennström, Pau Montesinos, Carmen Botella, Juan Miguel Bergua Burgues, Raimundo Garcia, Josefina Serrano, Mariluz Amigo, Patricia Garcia Ramirez, Claudia Sossa, Juan Manuel Alonso-Dominguez, Hartmut Döhner, Konstanze Döhner, Daniela Späth, Michael Kühn, Claudia Lengerke, Hans-Jörg Tischler, Christoph Röllig, Leo Ruhnke, Christian Thiede, Andreas Burchert, Hubert Serve, Carsten Mueller-Tidow, Claudia Baldus, Jurjen Versluis, Peter Valk, Daniel Kristensen, Anne Stidsholt Roug, Jiri Mayer, Mika Kontro, Pia Ettala, Vladimir Lazarevic, Christian Recher

Blood (2025) 146 (Supplement 1): 991.

https://doi.org/10.1182/blood-2025-991

Published: 2025

Journal Articles

Induction chemotherapy with a single anthracycline-containing cycle in younger adults with newly diagnosed AML – the french backbone intergroup (BIG)-1 study on behalf of the filo, ALFA, and SFGM-TC study groups

Blood (2025) 146 (Supplement 1): 43.

https://doi.org/10.1182/blood-2025-43

Published: 2025

Journal Articles

Therapy-related core binding factor Acute Myeloid Leukemia – a Study of the french acute leukemia intergroup

Blood (2025) 146 (Supplement 1): 37.

https://doi.org/10.1182/blood-2025-37

Published: 2025

Journal Articles

Deep immune signature of immune-mediated aplastic anemia patients shows distinct subsets of regulatory T cells associated with response to treatment: Results from the phase 3, randomized EBMT race clinical trial

Blood (2025) 146 (Supplement 1): 26.

https://doi.org/10.1182/blood-2025-26

Published: 2025

Journal Articles

PPM1D mutations confer resistance to venetoclax in pre-leukemic and AML populations

Jules Higue, Zhen Xu, Zhi Han Yeoh, Ing Tiong, Natasha Anstee, Michelle Jahja, Chyn Chua, Giovanna Pomillio, Hai Vu Nguyen, Lucie Rigolot, Véronique De Mas, Eric Delabesse, Christian Recher, Ian Majewski, Andrew Wei

Blood (2025) 146 (Supplement 1): 1507.

https://doi.org/10.1182/blood-2025-1507

Published: 2025

Journal Articles

Impact of G-CSF in AML patients treated with venetoclax and azacitidine: A dataml registry study

Blood (2025) 146 (Supplement 1): 3445.

https://doi.org/10.1182/blood-2025-3445

Published: 2025

Journal Articles

ALIDHE: An ongoing open-label phase 3b study investigating ivosidenib with azacitidine in clinical practice in adult patients with newly diagnosed mutant isocitrate dehydrogenase 1 (mIDH1) Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (IC)

Blood (2025) 146 (Supplement 1): 3443.

https://doi.org/10.1182/blood-2025-3443

Published: 2025

Journal Articles

CYP3A4 inhibitors (CYP3A4i) and myelosuppression in patients (Pts) with newly diagnosed mutant isocitrate dehydrogenase 1 (mIDH1) Acute Myeloid Leukemia (AML) in the phase 3 AGILE study

Andre Schuh, Pau Montesinos, Christian Recher, Michael Heuser, Susana Vives, Ewa Zarzycka, Marta Riva, Rodrigo Calado, Su-Peng Yeh, Courtney DiNardo, Mohammad Hossain, Jianan Hui, Diego Gianolio, Assaf Vestin, Rui Ding, Prapti Patel, Stéphane De Botton, Hartmut Döhner, Jianxiang Wang

Blood (2025) 146 (Supplement 1): 3440.

https://doi.org/10.1182/blood-2025-3440

Published: 2025

Journal Articles

Camelot-2: A phase 3 randomized, double-blind, placebo-controlled, study of bleximenib, venetoclax and azacitidine for the treatment of participants with newly diagnosed Acute Myeloid Leukemia harboring KMT2A rearrangements or NPM1 mutations, who are ineligible for intensive chemotherapy

Blood (2025) 146 (Supplement 1): 3429.

https://doi.org/10.1182/blood-2025-3429

Published: 2025

Journal Articles

Real-world overall survival in patients with Acute Myeloid Leukemia treated with ivosidenib plus azacitidine in the USA: Trinetx-based analysis

Joshua Zeidner, Priyanka Mehta, Alfonso Piciocchi, Anna Candoni, Pierre-Yves Dumas, Menno Van Roosmalen, Annett Kucka, Romyka Ferhi, Christian Recher

Blood (2025) 146 (Supplement 1): 3401.

https://doi.org/10.1182/blood-2025-3401

Published: 2025

Journal Articles

Randomized study of high-dose cytarabine with or without dexamethasone as post-remission therapy in younger adults with newly diagnosed AML – the french backbone intergroup (BIG)-1 study on behalf of the filo, ALFA, and SFGM-TC study groups

Blood (2025) 146 (Supplement 1): 881.

https://doi.org/10.1182/blood-2025-881

Published: 2025

Journal Articles

Transfusion independence with momelotinib regardless of baseline erythropoietin levels in the Phase 3 SIMPLIFY-1 trial

Stephen Oh, Juan Carlos Hernandez Boluda, Jean-Jacques Kiladjian, Viviane Dubruille, Christian Recher, Alexandre Lockhart, Chandan Kumar, Hanny Musa, Jasmine Sahni, Dwaipayan Patnaik, Claire Harrison

Blood (2025) 146 (Supplement 1): 2025.

https://doi.org/10.1182/blood-2025-2025

Published: 2025

Journal Articles

Hematopoietic architecture drives biological and metabolic heterogeneity and predicts treatment-free remission outcomes in chronic myeloid leukemia

Isabelle De Araujo, Mathilde Marlas, Marie-Laure Nicolau, Inès Vergnolle, Lucie Donaty, Isabelle Luquet, Alban Canali, Lucie Rigolot, Laetitia Largeaud, Eric Delabesse, Véronique De Mas, Leopoldine Lapierre, Sarah Bertoli, Christian Recher, Jean-Emmanuel Sarry, Francoise Huguet, Suzanne Tavitian, Francois Vergez

Blood (2025) 146 (Supplement 1): 3787.

https://doi.org/10.1182/blood-2025-3787

Published: 2025

Journal Articles

Validation of the FL/IL6 score, a new dynamic cytokine-based risk-model in adults with acute myeloid leukemia, a prospective multicentre filo study.

Blood (2025) 146 (Supplement 1): 5247.

https://doi.org/10.1182/blood-2025-5247

Published: 2025

Journal Articles

Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed AML with CBFB::MYH11 or RUNX1::RUNX1T1 fusions: Real-world outcomes based on international registry data

Blood (2025) 146 (Supplement 1): 5230.

https://doi.org/10.1182/blood-2025-5230

Published: 2025

Journal Articles

Outcomes of older or unfit AML patients admitted to intensive care unit in the venetoclax era

Blood (2025) 146 (Supplement 1): 5225.

https://doi.org/10.1182/blood-2025-5225

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Post-induction minimal residual disease assessment by flow cytometry and molecular biology enables prognostic stratification of patients with NPM1-mutated Acute Myeloid Leukemia: A dataml registry study.

Comprehensive mutational profiling and clinical outcome of adults AML with NUP98 rearrangement

Impact of midostaurin in younger AML patients intensively treated with high-dose anthracycline

Real life study of ivosidenib in either monotherapy or combined with azacytidine for first line mutant IDH1 AML: A study from the french AML intergroup ALFA/filo

The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy

Induction chemotherapy with a single anthracycline-containing cycle in younger adults with newly diagnosed AML – the french backbone intergroup (BIG)-1 study on behalf of the filo, ALFA, and SFGM-TC study groups

Therapy-related core binding factor Acute Myeloid Leukemia – a Study of the french acute leukemia intergroup

Deep immune signature of immune-mediated aplastic anemia patients shows distinct subsets of regulatory T cells associated with response to treatment: Results from the phase 3, randomized EBMT race clinical trial

PPM1D mutations confer resistance to venetoclax in pre-leukemic and AML populations

Impact of G-CSF in AML patients treated with venetoclax and azacitidine: A dataml registry study

ALIDHE: An ongoing open-label phase 3b study investigating ivosidenib with azacitidine in clinical practice in adult patients with newly diagnosed mutant isocitrate dehydrogenase 1 (mIDH1) Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (IC)

CYP3A4 inhibitors (CYP3A4i) and myelosuppression in patients (Pts) with newly diagnosed mutant isocitrate dehydrogenase 1 (mIDH1) Acute Myeloid Leukemia (AML) in the phase 3 AGILE study

Camelot-2: A phase 3 randomized, double-blind, placebo-controlled, study of bleximenib, venetoclax and azacitidine for the treatment of participants with newly diagnosed Acute Myeloid Leukemia harboring KMT2A rearrangements or NPM1 mutations, who are ineligible for intensive chemotherapy

Real-world overall survival in patients with Acute Myeloid Leukemia treated with ivosidenib plus azacitidine in the USA: Trinetx-based analysis

Randomized study of high-dose cytarabine with or without dexamethasone as post-remission therapy in younger adults with newly diagnosed AML – the french backbone intergroup (BIG)-1 study on behalf of the filo, ALFA, and SFGM-TC study groups

Transfusion independence with momelotinib regardless of baseline erythropoietin levels in the Phase 3 SIMPLIFY-1 trial

Hematopoietic architecture drives biological and metabolic heterogeneity and predicts treatment-free remission outcomes in chronic myeloid leukemia

Validation of the FL/IL6 score, a new dynamic cytokine-based risk-model in adults with acute myeloid leukemia, a prospective multicentre filo study.

Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed AML with CBFB::MYH11 or RUNX1::RUNX1T1 fusions: Real-world outcomes based on international registry data

Outcomes of older or unfit AML patients admitted to intensive care unit in the venetoclax era

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only